Mark Wiggins Net Worth

The estimated Net Worth of Mark C Wiggins is at least $6.06 Million dollars as of 29 December 2020. Mr. Wiggins owns over 1,000 units of TRACON Pharmaceuticals Inc stock worth over $945 and over the last 20 years he sold TCON stock worth over $5,455,311. In addition, he makes $603,016 as Chief Business Officer at TRACON Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Wiggins TCON stock SEC Form 4 insiders trading

Mark has made over 34 trades of the TRACON Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of TCON stock worth $10,570 on 29 December 2020.

The largest trade he's ever made was exercising 89,645 units of TRACON Pharmaceuticals Inc stock on 15 October 2007 worth over $5,895,952. On average, Mark trades about 8,853 units every 102 days since 2004. As of 29 December 2020 he still owns at least 13,700 units of TRACON Pharmaceuticals Inc stock.

You can see the complete history of Mr. Wiggins stock trades at the bottom of the page.

Mark Wiggins biography

Mark C. Wiggins serves as Chief Business Officer of the Company. Prior to joining us, Mr. Wiggins served as Chief Executive Officer at selectION Therapeutics, Inc., from 2017 to 2018, Senior Vice President of Corporate and Business Development at Elcelyx Therapeutics from 2012 to 2015, and Chief Business Officer at Mpex Pharmaceuticals from 2009 to 2011. Prior to this, he served as Executive Vice President of Corporate and Business Development at Biogen Idec, Inc. from 2003 to 2009 and Vice President of Marketing and Business Development at IDEC Pharmaceuticals from 1998 to 2003. Mr. Wiggins also previously served as Head of U.S. Business Development at Schering-Plough (now Merck), in addition to roles at Pfizer and Johnson & Johnson. Mr. Wiggins currently serves on the board of directors of Zogenix and SelectION. He received a B.S. in finance from Syracuse University and an M.B.A. from the University of Arizona.

What is the salary of Mark Wiggins?

As the Chief Business Officer of TRACON Pharmaceuticals Inc, the total compensation of Mark Wiggins at TRACON Pharmaceuticals Inc is $603,016. There are 2 executives at TRACON Pharmaceuticals Inc getting paid more, with Charles Theuer having the highest compensation of $1,085,320.

How old is Mark Wiggins?

Mark Wiggins is 64, he's been the Chief Business Officer of TRACON Pharmaceuticals Inc since 2018. There are 4 older and 10 younger executives at TRACON Pharmaceuticals Inc. The oldest executive at TRACON Pharmaceuticals Inc is William LaRue, 69, who is the Independent Director.

What's Mark Wiggins's mailing address?

Mark's mailing address filed with the SEC is C/O ZOGENIX, INC., 5858 HORTON STREET, #455, EMERYVILLE, CA, 94608.

Insiders trading at TRACON Pharmaceuticals Inc

Over the last 10 years, insiders at TRACON Pharmaceuticals Inc have traded over $6,301,907 worth of TRACON Pharmaceuticals Inc stock and bought 27,278,043 units worth $151,387,355 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, TRACON Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $15,278. The most recent stock trade was executed by Management Inc. Opaleye on 10 November 2023, trading 4,764,008 units of TCON stock currently worth $1,381,562.

What does TRACON Pharmaceuticals Inc do?

tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w

Complete history of Mr. Wiggins stock trades at Biogen Inc, TRACON Pharmaceuticals Inc und Zogenix Inc

TRACON Pharmaceuticals Inc executives and stock owners

TRACON Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Charles Theuer,
  President, Chief Executive Officer, Director
• Dr. Charles P. Theuer M.D., Ph.D.,
  CEO, Pres & Director
• Mark Wiggins,
  Chief Business Officer
• Mark C. Wiggins M.B.A.,
  Chief Bus. Officer
• Scott Brown,
  Chief Accounting Officer
• Scott B. Brown CPA, M.S.,
  Chief Financial Officer
• Suzy Benedict,
  Executive Vice President - Regulatory Affairs
• Stephen Worland,
  Independent Director
• J. Rainer Twiford,
  Independent Director
• Martin Mattingly,
  Independent Director
• William LaRue,
  Independent Director
• Saundra Pelletier,
  Director
• Bonne Adams,
  Executive Vice President - Clinical Operations
• Dr. Brenda Marczi Pharm.D., Pharmd Mba,
  Sr. VP of Regulatory Affairs
• Ya Huang,
  Exec. Director of Statistical Programming
• Bonne Adams,
  Exec. VP of Clinical Operations
• Dr. James L. Freddo,
  Chief Medical Officer
• Shahe Garabedian,
  Sr. VP & Head of Quality Assurance
• Ravi Nea Partners 14, L.P.N...,
  
• Peter W.Nea Partners 14, L....,
  
• Scott Dnea Partners 14, L.P...,
  
• Patrick Jnea Partners 14, L...,
  
• David Mnea Partners 14, L.P...,
  
• Anthony A. Jr.Nea Partners ...,
  
• Forestnea Partners 14, L.P....,
  
• Peter Jnea Partners 14, L.P...,
  
• M Jamesnea Partners 14, L.P...,
  
• Capital, Llc Ikarian Health...,
  
• Patricia L Bitar,
  CFO
• Forest Baskett,
  10% owner
• Patrick J Kerins,
  10% owner
• H Casey Logan,
  Chief Business Officer
• Peter J Barris,
  10% owner
• M James Barrett,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• David M Mott,
  10% owner
• Scott D Sandell,
  10% owner
• Peter W. Sonsini,
  10% owner
• Enterprise Associates 14, L...,
  
• Tracon Investment Fund Ii, ...,
  
• Paul Edward Walker,
  Director
• Ronald L Shazer,
  Chief Medical Officer
• Krishna Kittu Kolluri,
  10% owner
• Ravi Viswanathan,
  10% owner
• Theodore T Wang,
  Director
• Cross Border Opportunities ...,
  
• Cross Border Opportunities ...,
  
• Harry R Weller,
  10% owner
• Enterprise Associates 14, L...,
  
• Ryan D Drant,
  10% owner
• Super V3 Investment Limited...,
  10% owner
• Management Inc. Opaleye,
  10% owner
• Capital, Llc Ikarian Health...,
  
• Lisa Johnson Pratt,
  Director
• Carol C. Lam,
  Director